Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting ...

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but ...

Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to ...

Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech ...

Discovery remains essential, but its value depends on builders and systems capable of carrying it through. The organizations ...

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli ...

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the ...

The government has announced “most-favored-nation” pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s spending on prescription drugs.

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato ...

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on key decisions and work to speed early drug research.

The latest installment in BioPharma Dive’s data visualization series features a closer look at Novo's stock performance and the recent run of fundraising success for AI drug discovery startups.